Merck & Company, Inc. (new) (MRK) analyst actions
MRK analyst actions moved a median of +0.02% by the close. Rating and price-target actions on MRK in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MRK overview →
14 measured MRK analyst action events.
Where these MRK analyst actions landedvs 14 measured MRK analyst action reactions
| Middle 50% of MRK analyst action reactions | -0.89% to +1.03% |
|---|---|
| Median reaction (to close) | +0.02% |
| Measured reactions | 14 |
Point-in-time · zero look-ahead
Half of the 14 MRK analyst action events with a measured close landed between -0.89% and +1.03%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration | Press release | +0.39% | +0.36% | |
| Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC | Press release | +0.36% | -0.96% | |
| Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases | Press release | +0.14% | -0.03% | |
| HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy | Press release | +0.00% | -1.18% | |
| IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer | Press release | -0.17% | +1.78% | |
| Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate | Press release | +0.26% | +1.77% | |
| IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Press release | +0.42% | +1.19% | |
| Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma | Press release | -0.15% | -0.98% | |
| Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults | Press release | +0.17% | +2.10% | |
| Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema | Press release | -0.38% | -0.68% | |
| Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia | Press release | -0.21% | +0.07% | |
| IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer | Press release | -0.12% | +0.56% | |
| Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer | Press release | -0.47% | -2.42% | |
| REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer | Press release | +0.28% | -0.62% |
Keep exploring
More MRK: earnings → · SEC filings → · MRK overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS (MNTA) | 1,355 | 0.00% | 46% |
| Clovis Oncology, Inc. (CLVS) | 1,349 | -0.20% | 47% |
| Humana Inc. (HUM) | 1,306 | +0.02% | 51% |
| WELLCARE HEALTH PLANS (WCG) | 1,292 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.